Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
10.60
-0.31 (-2.84%)
Mar 5, 2026, 4:00 PM EST - Market closed
Benitec Biopharma Employees
Benitec Biopharma had 19 employees as of June 30, 2025. The number of employees increased by 3 or 18.75% compared to the previous year.
Employees
19
Change (1Y)
3
Growth (1Y)
18.75%
Revenue / Employee
n/a
Profits / Employee
-$2,321,474
Market Cap
363.10M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Neurogene | 107 |
| Aclaris Therapeutics | 73 |
| Atea Pharmaceuticals | 56 |
| Candel Therapeutics | 38 |
| NovaBridge Biosciences | 32 |
| Avalo Therapeutics | 23 |
| Climb Bio | 18 |
| Relmada Therapeutics | 17 |
BNTC News
- 4 weeks ago - Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade - Seeking Alpha
- 7 weeks ago - Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response - GlobeNewsWire
- 3 months ago - Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 4 months ago - Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering - GlobeNewsWire
- 4 months ago - Benitec Biopharma Inc. Announces Proposed Public Offering - GlobeNewsWire
- 4 months ago - Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 - GlobeNewsWire
- 4 months ago - Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewsWire
- 5 months ago - Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update - GlobeNewsWire